Functionally, cDC1s excel at cross-presenting tumor antigens on MHC-I to CD8+ T cells, initiating robust cytotoxic responses (50), while cDC2s promote CD4+ T cell polarization through MHC-II pathways, modulating Th1, Th2, and Th17 responses. The gene discussed is CD8A; the disease is neoplasm.